Proteomic analysis of early diabetic retinopathy reveals mediators of neurodegenerative brain diseases by Sundstrom, JM et al.
Retina
Proteomic Analysis of Early Diabetic Retinopathy Reveals
Mediators of Neurodegenerative Brain Diseases
Jeffrey M. Sundstrom,1 Cristina Hernández,2,3 Sarah R. Weber,1 Yuanjun Zhao,1 Mitchell
Dunklebarger,1 Natalia Tiberti,4 Tatiana Laremore,5 Olga Simó-Servat,2,3 Marta Garcia-Ramirez,2,3
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PURPOSE. Current evidence suggests that retinal neurodegeneration is an early event in the
pathogenesis of diabetic retinopathy. Our main goal was to examine whether, in the diabetic
human retina, common proteins and pathways are shared with brain neurodegenerative
diseases.
METHODS. A proteomic analysis was performed on three groups of postmortem retinas
matched by age: nondiabetic control retinas (n ¼ 5), diabetic retinas without glial activation
(n ¼ 5), and diabetic retinas with glial activation (n ¼ 5). Retinal lysates from each group
were pooled and run on an SDS-PAGE gel. Bands were analyzed sequentially by liquid
chromatography-mass spectrometry (LC/MS) using an Orbitrap Mass Spectrometer.
RESULTS. A total of 2190 proteins were identified across all groups. To evaluate the association
of the identified proteins with neurological signaling, significant signaling pathways belonging
to the category ‘‘Neurotransmitters and Other Nervous System Signaling’’ were selected for
analysis. Pathway analysis revealed that ‘‘Neuroprotective Role of THOP1 in Alzheimer’s
Disease’’ and ‘‘Unfolded Protein Response’’ pathways were uniquely enriched in control
retinas. By contrast, ‘‘Dopamine Degradation’’ and ‘‘Parkinson’s Signaling’’ were enriched
only in diabetic retinas with glial activation. The ‘‘Neuregulin Signaling,’’ ‘‘Synaptic Long Term
Potentiation,’’ and ‘‘Amyloid Processing’’ pathways were enriched in diabetic retinas with no
glial activation.
CONCLUSIONS. Diabetes-induced retinal neurodegeneration and brain neurodegenerative
diseases, such as Alzheimer’s and Parkinson’s diseases, share common pathogenic pathways.
These findings suggest that the study of neurodegeneration in the diabetic retina could be
useful to further understand the neurodegenerative processes that occur in the brain of
persons with diabetes.
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Diabetic retinopathy (DR) remains a leading cause ofpreventable blindness in developed countries.1 Current
treatments target late stages of DR when vision already has
been significantly affected. A better understanding of the
pathogenesis of DR would permit the development of more
efficient preventative/interventional strategies against its early
stages, before overt microvascular damage or vision loss
occurs.2–4
DR long has been considered exclusively a microcirculatory
disease of the retina. However, current evidence suggests that
retinal neurodegeneration, leading to significant thinning of the
neural retina,5,6 is an early event in the pathogenesis of DR and
may participate in the development of microvascular abnor-
malities.3,7,8
Neural apoptosis and glial activation (GA; also known as
reactive gliosis) are the most important histological features of
retinal neurodegeneration. GA is the general response to injury
in glial cells and is characterized by aberrant expression of glial
fibrillary acidic protein (GFAP). This intermediate filament
protein is expressed in the normal retina mostly by astrocytes
and minimally by Müller cells. In diabetes, however, Müller cells
acquire prominent GFAP immunoreactivity, whereas astrocytes
progressively lose GFAP expression.9,10 It should be noted that
Müller cells, the primary glial cells in the retina, produce factors
capable of modulating blood flow, vascular permeability, and
cell survival, and their processes are adjacent to the blood
vessels in the retina. Therefore, injury to these cells has an
essential role in the pathogenesis of early microcirculatory
abnormalities and the impairment of neurovascular coupling in
the retina.11 In addition, GA also may induce neural cell death
by several mechanisms, including glutamate excitotoxicity.3 We
used GFAP immunoreactivity in diabetic donors as a marker for
GA and a parameter for the classification into groups with (high
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GFAP immunoreactivity) and without (low GFAP immunore-
activity) retinal neurodegeneration.
Most of our cellular and molecular knowledge regarding the
mechanisms involved in the early stages of DR comes from
experimental models, and little is known regarding the
underlying biochemical changes that occur in the human
diabetic retina before the appearance of clinically observable
abnormalities. The development of proteomic analysis has
made it possible to analyze protein profiles in small samples,
and several studies have been performed using murine
models12–14 as well as human retinas.15 However, the difficulty
in obtaining human retina samples has led to vitreal fluid being
used to indirectly explore the events that occur in the
retina.16,17 With this approach, several proteome analyses of
human vitreous fluid from diabetic patients with proliferative
diabetic retinopathy18,19 or diabetic macular edema20,21
provided new insights into the pathogenesis of DR. Few
reports have examined the human retinal proteome in diabetic
patients. In this regard, a comparative analysis of the RPE
proteome between diabetic donors without DR and age-
matched controls has been published,22 but to the best of
our knowledge, a comparative analysis of the neuroretina has
not been reported.
We identified early changes in DR using an unbiased
proteomics approach. For this purpose, proteomic profiles of
control retinas were compared to diabetic retinas obtained
from patients known to be without classic vascular lesions that
clinically define DR. The diabetic retinas were split further into
two groups according the presence or absence of GA. This
approach permitted us to identify the main proteins and
metabolic pathways involved in these early stages of DR. Our
study focuses on the most relevant proteins related to
neuroregulatory and neurodegenerative pathways unique to
each of the three groups (control retinas, and diabetic retinas
with and without GA), with special emphasis on the proteins
and pathways shared with brain neurodegenerative diseases.
METHODS
Tissue Acquisition
Institutional review board approval was obtained for this study
from Vall d’Hebron University Hospital. This study adheres to
all tenets of the Declaration of Helsinki. Postmortem retinal
tissue was acquired from the Blood and Tissue Bank of Vall
d’Hebron University Hospital. Inclusion criteria were a fundus
examination performed by indirect ophthalmoscopy or fundus
photographs within two years before death documenting
absence of microvascular abnormalities associated with DR.
The control group (C; n ¼ 5) included patients without
diabetes. The diabetes group included patients with diabetes
and minimal (D, n ¼ 5) or abundant (DþGFAP; n ¼ 5) GFAP
immunoreactivity in the retina, Average death to harvest time
was 3.8 hours. After enucleation, one eye of each donor was
snap-frozen at 808C and stored until assayed for mRNA and
proteins. The other eye was fixed in 4% (wt/vol) paraformal-
dehyde and embedded in paraffin for the immunohistochem-
istry (IHC) study.
Immunohistochemistry
The retina was sectioned and IHC was performed as described
previously.23 GA was assessed by masked observers using the
scoring system based on methods reported previously by
Anderson et al.24 A GA score of 4 or 5 indicated a high degree
of GFAP, whereas a score of 1 to 3 indicated a low degree of
GFAP staining. Apoptosis was evaluated by TUNEL. The
number of TUNEL-positive cells (green) was recorded in three
fields of each retina that covered 212 3 212 lm. Images were
acquired with a confocal laser scanning microscope (FV1000,
Olympus. Hamburg, Germany).
Microglial activation was assessed by ionized calcium-
binding adapter molecule 1 (Iba-1) immunofluorescence.
Retina sections were incubated overnight in a humid chamber
at 48C with goat anti-Iba-1 (Abcam, Madrid, Spain). Then,
samples were washed and incubated for 60 minutes with anti-
goat Alexa 488 (1:200; Molecular Probes, Eugene, OR, USA).
After washing, sections were mounted in Vectashield (Vector
Labs, Burlingame, CA, USA) mounting medium with 40,6-
diamidino-2-phenylendole (DAPI). Images were acquired with a
confocal laser scanning microscope (FV1000; Olympus) with a
360 objective. Images size were 1024 3 1024 pixels.
Fluorescent values were obtained with the software Olimpus
Fluoview (v.4.2) in the confocal images (oib) with an ROI
plugin and with background substraction.
Retinal Lysis
Protein extracts from the whole neuroretina were prepared by
homogenization with radioimmunoprecipitation assay (RIPA)
buffer (R0278; Sigma Aldrich Quimca S.A., Madrid, Spain)
containing protease inhibitor (P8340; Sigma Aldrich Quimca
S.A.) and 20 mM NaF, 2 mM Na3VO4, 2 mM PMSF. Extracts
were cleared by microcentrifugation at 10,000g for 10 minutes
at 48C. The supernatant was aliquoted and stored at 808C.
Sample Preparation and Proteomic Analysis
A total of 60 lg protein (pooled from n ¼ 5 per group) was
subjected to SDS-PAGE using 4% to 20% gel. Following
electrophoresis, the gel was stained and each sample lane
was cut into 16 fragments (1 3 3 mm pieces). The fragments
were placed in Eppendorf tubes and digested with trypsin
using the following method. Briefly, fragments were destained
with 8 mg/mL (100 mM) ammonium bicarbonate (NH4HCO3)
in 50% acetonitrile (ACN) at pH 8.5. The samples were reduced
with tris(2-carboxyethyl)phosphine (30 mg/mL) in H2O,
incubated at 48C for 2 hours, then alkylated with iodoaceta-
mide (IAA; 18 mg/mL [100 mM] in 8 mg/mL NH4HCO3, freshly
made and kept in the dark) at room temperature for 30
minutes. The alkylating buffer was removed and the samples
were washed with destaining buffer. The gel fragments were
dehydrated using ACN. Samples were digested with trypsin (10
ng/lL in 8 mg/mL NH4HCO3) at 378C overnight. The tryptic
peptides were transferred to fresh tubes. Additional peptides
were extracted using 0.1% formic acid in 50% ACN and added
to the original fractions. The samples then were filtered
(NanoSep MF GHP 0.45 lm) and concentrated before mass
spectrometry (MS) analysis.
Nano-liquid chromatography MS (LC/MS)2 was performed
to detect peptides; 1 mL samples were loaded onto an Acclaim
PepMap100 trapping column (100 lm 3 2 cm, C18, 5 lm, 100
Å; Thermo Fisher Scientific, Waltham, MA, USA) at a flow rate
of 20 lL/min using 4% aqueous ACN, and 0.1% formic acid (FA)
as a mobile phase. The peptides were separated on an Acclaim
PepMap RSLC column (75 lm 3 15 cm, C18, 2 lm, 100 Å;
Thermo Fisher) with a 90-minute 4% to 40% linear gradient of
ACN in water containing 0.1% formic acid. The gradient was
delivered by a Dionex Ultimate 3000 nano-LC system (Thermo
Fisher) at 300 nL/min. An LTQ Orbitrap Velos mass spectrom-
eter (Thermo Fisher) was set to acquire data using the
following data-dependent parameters: full FT MS scan at R
60,000 followed by 10 ion-trap MS2 scans on most intense
precursors with CID activation. Only the precursors with
charge states þ2 and higher were selected for MS2; mono-
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isotopic precursor selection was enabled, and the isolation
window was 3 m/z. Dynamic exclusion duration was 15
seconds, repeated once over 30-second repeat duration.
Proteomic Data Analysis
The mass spectra were processed using Proteome Discoverer
1.3 (Thermo Fisher). The MS2 data were analyzed with Sequest
(Thermo Fisher, version 1.3.0.339) set up to search a database
combining current human_contam_fasta proteome,
up1.4.0.288, Uniprot, and the common contaminants sequenc-
es, a total of 49,426 entries. The following search parameters
were used: precursor tolerance 20 parts per million (ppm),
fragment tolerance 0.8 Daltons (Da), dynamic modifications
included Oxidation (þ15.995 Da, Met) and Deamidation
(þ0.984 Da, Asn, Gln), static modification was carbamidometh-
yl (þ57.021 Da, Cys). The resultant Sequest files were parsed
into Scaffold (version 4.6.1) for validation filtering and
generation of nonredundant proteins. Uniprot was used to
remove any obsolete protein identifications.
Pathway and Gene Ontology Analysis
Pathway enrichment analysis was performed using the
Ingenuity Pathway Analysis (IPA) bioinformatics platform
(provided in the public domain at www.Qiagen.com). For
each of the three individual sample sets, identification of
significantly represented pathways was performed using a
Log P value for each of the identified pathways. The
significance value for each pathway was calculated using the
right-tailed Fisher’s exact test. The P values were corrected
using the Benjamini-Hochberg (B-H) correction to control for
the false discovery rate. A significance value cutoff of B-H P
value 0.001 was selected to identify shared and unique
pathways within each sample set. To evaluate the association
of the identified proteins with neurological signaling, signifi-
cant signaling pathways belonging to the category ‘‘Neuro-
transmitters and Other Nervous System Signaling’’ were
selected for analysis.
Pathway activation analysis was performed using the
comparison Analysis function on IPA. Briefly, a count value
of one was added to each spectral count observation. For each
protein, 2-fold changes (FCs) were computed (D/C and
DþGFAP/C). The Log2(FC) was calculated for each protein
within each of the two comparison groups. This dataset was
uploaded to IPA, and only those proteins having a FC 0.5 or
‡1.5 were included in the final analysis.
RESULTS
Demographics and Sample Classification
As described above, three groups of samples were analyzed;
control (C), diabetes (D) and diabetes with GFAP expression
(DþGFAP). The average ages of the groups were similar (C ¼
71.8 6 7.1; D¼ 67.2 6 7.2, DþGFAP¼ 68.6 6 8.8). The main
clinical features and causes of death of diabetic and nondia-
betic donors are summarized in Table 1. Images of GFAP
immunoreactivity in retinal sections from each donor included
in the study are shown in Figure 1. Classification of patients by
GFAP staining was verified by GFAP abundance using spectral
counts (C ¼ 122.79; D ¼ 240.39; DþGFAP ¼ 528.01). The
progressive increase in GFAP observed in groups D and
DþGFAP was associated with an increase in apoptotic rate
(Fig. 2), as well as microglial activation assessed by Iba-1
immunofluorescence (Fig. 3).
Overview of Retinal Proteome
Sample integrity was assessed with total protein stain of the
SDS-PAGE gel (Supplemental Material). Although the appear-
ance of the gel suggested lack of signs of sample degradation,
the presence of degradation cannot be completely ruled out
based only on this evidence. However, the quality of the
proteomic data was confirmed by the following parameters:
99% confidence for protein identification, 95% confidence for
peptide assignment, 0.9% protein false discovery rate (FDR),
and 0.03% peptide FDR. There were 2076, 2107, and 1906
proteins identified in the C, D, and DþGFAP groups,
respectively. A complete list of the identified peptides and
proteins is available for download (Supplementary Material).
Obsolete proteins were filtered and removed from all
further analyses. Similarity among groups was assessed by
percent homology for each study group. Figure 4 shows that
1414, 1487, and 1080 proteins were identified retinas in the C,
D, and DþGFAP groups, respectively. Homology among all
three sample groups encompassed 37% (n ¼ 736) of the total
assigned proteins. Between-group homology was greatest
between groups C and D with an 18.1% similarity (n ¼ 360),
whereas the lowest was between groups C and DþGFAP, with
only a 3.6% similarity (n ¼ 72) between assigned protein IDs.
The number of unique proteins expressed in each group was
statistically similar (C ¼ 246, D ¼ 303, and DþGFAP ¼ 184) as
were the number of co-expressed proteins between any two
TABLE. Clinical Characteristics of Non-Diabetic Donors and Diabetic Donors Included in the Study
Group D, N ¼ 5 Group DþGFAP, N ¼ 5 Group C, N ¼ 5 P Value
Age, y 68.6 6 8.8 67.2 6 7.2 71.8 6 7.1 n.s.
Sex, M/F 3/2 4/1 4/1 n.s.
Type of diabetes (1, 2) 0/5 0/5
Diabetes treatment
Diet only 0 1
Oral agents 3 3
Insulin 1 0
Insulin þ oral agents 1 1
Cause of death
Coronary disease 2 1 1
Brain hemorrhage 1 1 2
Respiratory insufficiency 2 2 1
Others 1 1
Death to harvest, h 3.6 6 0.8 4.0 6 1.0 3.8 6 0.83 n.s.
Comparisons of continuous variables were performed using Student’s t-test. Data are presented as mean 6 SD. Categorical variables were
compared using Fisher’s exact test. Levels of statistical significance were set at P < 0.05. n.s., not significant.
Proteomics of Preclinical Diabetic Retinopathy IOVS j May 2018 j Vol. 59 j No. 6 j 2266
Downloaded from iovs.arvojournals.org on 03/14/2019
groups (C and D¼ 360; C and DþGFAP¼ 72, D and DþGFAP¼
88).
Pathway Analysis
Pathway analysis was performed by IPA using the pathway
enrichment function. A complete list of enriched pathways
identified in each sample is available in the supplemental
material section for download. Significant (B-H P  0.001)
pathways identified in each of the three types of biological
samples were compared. With this approach, we noted the
presence or absence of canonical pathways involved in
neuroregulatory cell functions in each group. In general,
significant homology was seen among all three groups with a
total of 73 shared pathway assignments (58% of total pathway
assignments). However, a substantial number of unique
pathways were identified for each condition (Fig. 5). Unique
pathway assignments were greatest within the D group (n ¼
23), while the C and DþGFAP groups had six unique pathways
each. To identify the unique pathways related to neurodegen-
erative processes of each group, the Ontology and Function
algorithm within IPA was used to restrict the enriched pathway
dataset to those related to ‘‘Neurotransmitters and Other
Nervous System Signaling’’ among the unique pathways of
each group. The data then were examined in a different
manner to confirm the aforementioned results. The results are
included in the Supplemental Material, and a visual represen-
tation of unique pathways alone is provided in Figure 6.
Additionally, pathway activation analysis allowed activation
and deactivation statuses to be compared between groups.
This is represented by an activation z-score generated by IPA,
which takes into account the presence of regulatory proteins
and the direction in which these proteins push the pathway
based on published literature. A positive z-score represents
pathway activation, while a negative z-score represents
pathway inhibition. Those scores with a magnitude ‡2 are
considered significant. Significantly activated/inhibited path-
ways are included along with unique pathways in the
Supplemental Material. The ‘‘Neuroprotective Role of THOP1
in Alzheimer’s Disease’’ and ‘‘Unfolded Protein Response’’
pathways were uniquely identified only in group C, suggesting
the loss of these neuroprotective pathways in groups D and
DþGFAP retinas. Group D was uniquely enriched in the
‘‘Neuroregulin Signaling,’’ ‘‘Synaptic Long Term Potentiation,’’
and ‘‘Amyloid Processing’’ pathways. Two neurologic path-
ways, ‘‘Dopamine Degradation’’ and ‘‘Parkinson’s Signaling,’’
were uniquely enriched in group DþGFAP. These results are
highlighted in Figure 5.
DISCUSSION
The present proteomic study allowed identification of pro-
teome changes involved in the pathological processes that
occur in the early stages of DR and how these processes vary
with disease severity, as marked by the degree of GFAP
immunoreactivity. GFAP upregulation corresponds to GA, a
FIGURE 1. GFAP Immunohistochemistry. GFAP immunoreactivity in human retinas included in this study. C (C1–C5), D (D1–D5), and DþGFAP (D6–
D10) groups. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
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pathologic change that is associated with neurodegeneration
and precedes the overt microvascular abnormalities in DR.25 A
total of 35 pathways related to neurodegeneration or neuro-
regulation and specifically represented in a single group
(nondiabetic donors [C], diabetic donors without GA [D],
and diabetic donors with GA [DþGFAP]) have been identified.
We discussed the most relevant of these unique and
differentially activated pathways with special emphasis on
FIGURE 2. Retinal apoptosis. (A) TUNEL-positive immunofluorescence (green) in a representative donor from each group (C, D, and DþGFAP).
Nuclei were labeled with DAPI (blue). (B) Quantification of TUNEL-positive cells. The results were normalized taking into account the area
analyzed. Results are mean 6 SD. (C) white columns; (D) gray columns; DþGFAP: black columns. n¼ 5 donors by group. *P < 0.05 compared to
group C; **P < 0.001 compared to group C; #P < 0.01 compared to group D.
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those shared with brain neurodegenerative diseases. Interest-
ingly, such pathways recently been have implicated in the
pathogenesis of glaucoma by a similar proteomic analyses of
human retinas.26
Samples From Nondiabetic Donors
In the nondiabetic control (C) group, the ‘‘Neuroprotective
Role of THOP1 in Alzheimer’s Disease’’ and ‘‘Unfolded Protein
Response’’ pathways were uniquely present.
Neuroprotective Role of THOP1 in Alzheimer’s Dis-
ease. Amyloid b (Ab) accumulation is central to the current
view of Alzheimer’s disease pathogenesis. Thimet oligopepti-
dase (THOP1) has been implicated in amyloid precursor
protein (APP) processing as well as Ab clearance and,
therefore, it is postulated that THOP1 mediates a compensa-
tory neuronal response to increased Ab in the brain. In fact,
overexpression of THOP1 in primary cortical neurons is
neuroprotective against Ab toxicity.27
To the best of our knowledge, no data on the potential
neuroprotective role of THOP1 in the retina have been
reported, but numerous studies have examined the role of
Ab accumulation in retinal neurodegeneration. Specifically,
APP has been shown to be expressed in human RPE and RGC
cells.28,29 Additionally, it has been demonstrated that these cell
types, along with those of the inner nuclear layer, contain the
complete apparatus needed for Ab production.28–31 Further,
one study identified Ab plaques in the retinas of patients with
Alzheimer’s disease, suggesting similarity between the neuro-
degenerative processes of the retina and the brain in this
disease.32 Despite the lack of evidence of visible plaque
formation in retinas of diabetic donors or in diabetic animal
models, Ab accumulation has been detected in multiple layers
of the retina in a rabbit model of diabetes.33 Therefore, it also is
possible that the retinal accumulation of Ab is involved in the
neurodegenerative processes that occur in DR. Given the
plausibility of retinal Ab plaque formation and that the retina is
ontogenically a brain-derived tissue, it could be hypothesized
that THOP1 has neuroprotective functions in the retina similar
to its role in the brain. Identification of the THOP1 pathway
only in group C and not the others suggested that the
neuroprotective function of THOP1 may be lost early in the
diabetic retina. Whether the loss of this signaling pathway also
occurs in the brains of type 2 diabetic patients remains to be
elucidated, but could be a new mechanism to explain the
growing evidence regarding the association between type 2
diabetes and Alzheimer’s disease.34
Unfolded Protein Response. The unfolded protein
response (UPR) is a series of evolutionarily conserved signaling
pathways aimed at restoring homeostasis under conditions of
endoplasmic reticulum (ER) stress.35 Impairment of the UPR
has been involved not only in the accumulation of misfolded
FIGURE 3. Microglial activation. (A) Iba-1 immunolabeling of microglia (green) in a representative donor from each group (C, D, and DþGFAP).
Nuclei were labelled with DAPI (blue). Scale bar: 10 lm. (B) Quantification of Iba-1 fluorescent intensity. a.u., arbitrary units. Results are mean 6
SD. (C) white columns; (D) gray columns; DþGFAP: black columns. n¼ 5 donors by group. *P < 0.05 compared to the other groups.
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proteins in the brain of many neurodegenerative diseases,36
but also in DR.37,38
The initial response to misfolded proteins in a healthy cell is
to refold them back into their native shapes. This effect is
accomplished by a large, interdependent network of chaper-
one and co-chaperone proteins that help to prevent amyloid
assembly. The best-studied examples of chaperones are the
‘‘heat shock’’ proteins (Hsp). These proteins are especially
important in proteinopathic neurodegenerative diseases (e.g.,
Parkinson’s disease, Alzheimer’s disease, and diffuse Lewy body
disease), in which specific proteins misfold, aggregate, and kill
cells through proteotoxic stress.39 The balance between Hsp70
and Hsp90 is a major area of investigation, as upregulation of
Hsp70 and inhibition of Hsp90 in mammals have been shown
to reduce protein aggregation and toxicity.40 In our study, we
observed a significant decrease in multiple Hsp70s (e.g.,
Hsp70Kda-4, Hsp70Kds-4L) in retinas of diabetic patients with
GA, thus pointing to the accumulation of misfolded proteins as
a potential pathway involved in the neurodegenerative process
that occur in the early stages of DR. In contrast, we found an
increase of isoform 2 of Hsp90-a and the isoform 2 of the
stress-induced phosphoprotein 1 (STI1), an Hsp90 co-chaper-
one secreted by astrocytes, which protect neurons against Ab
oligomer-induced toxicity,41 suggesting a compensatory re-
sponse.
Samples From Diabetic Donors Without Glial
Activation
In diabetic patients without GA (D group), the following
neuroprotective pathways were upregulated: ‘‘Neuregulin
Signaling,’’ ‘‘Synaptic Long Term Potentiation,’’ and ‘‘Amyloid
Processing.’’
Neuregulin Signaling. The neuregulin family of ligands
(NRGs) are important in synaptogenesis and neuronal survival.
NRGs exhibit a neuroprotective role under inflammatory
conditions by acting in concert with the cholinergic anti-
inflammatory pathway.42 We found the ‘‘Neuregulin Signaling’’
pathway to be unique to the D group.
Although few data exist on NRGs in the retina, numerous
studies demonstrate neuroprotective effects of NRGs in the
FIGURE 4. Protein profile comparison. A total of 1414, 1487, and 1080
proteins were identified from retinas in the C, D, and DþGFAP groups,
respectively. A common core of 736 proteins was identified. Number of
unique proteins: C¼246, D¼303, and DþGFAP¼184. Groups C and D
shared 360 expressed proteins, Groups C and DþGFAP shared 72,
while groups D and DþGFAP shared 88.
FIGURE 5. Unique pathway assignments by study group. Significantly identified pathways in each of the three biological samples were compared.
Significant homology was seen among all three groups with a total of 73 shared pathway assignments (58% of total pathway assignments). However,
a substantial number of unique pathways were identified in each condition. Pathway assignments for the unique protein IDs in each sample group
were assigned using the IPA software platform. Selected pathways unique to each study group are highlighted in their respective boxes. Selected
pathways involved in neuroregulatory cell functions or neurodegeneration are bolded.
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central nervous system. For example, treatment with neure-
gulin after spinal cord injury enhances a neuroprotective
phenotype in inflammatory cells and leads to a decrease in
proinflammatory cytokines after injury.43 Furthermore, NRGs
exert a neuroprotective action against organophosphate
neurotoxicity by suppressing the proinflammatory response
of brain microglia.44 That the neuregulin pathway was unique
to the D group suggests that its neuroprotective effects occur
early in disease but are transient and are lost as the disease
progresses.
Synaptic Long Term Potentiation. Synaptic long term
depression (LTD) and synaptic long term potentiation (LTP) are
two variations on synaptic transmission that function in learning
and memory. LTP occurs in response to prolonged or high-
magnitude action potentials at a synapse, leading to an increased
response with subsequent stimuli of the same strength,45 LTD,
on the other hand, occurs in response to lower frequency action
potentials and leads to a decreased response with subsequent
stimuli of the same strength.45 These phenomena have been
studied primarily in the hippocampus and cerebellum and are
involved in synaptic plasticity. Although there are no studies
examining the roles of LTD and LTP on synaptic plasticity in the
diabetic retina, other retinal synaptic changes have been
documented in animal models. Specifically, VanGuilder et al.46
demonstrated a reduction in presynaptic expression of proteins
critical for synaptic transmission in diabetic rat retinas. We
found LTP activation to be unique to the D group. This finding is
inconsistent with several studies of the hippocampus in diabetic
rat models, which reported decreases in LTP relative to
controls.47–49 Further research is needed to elucidate the effects
of diabetes on LTP and LTD and to determine whether changes
in synaptic plasticity in the brain are generalizable to the retina.
Amyloid Processing. As discussed previously in relation
to THOP1 signaling, amyloid plaques composed of Ab are the
hallmark lesion of Alzheimer’s disease. Mutations in the APP or
enzyme that processes Ab result in familial Alzheimer’s disease
and Ab toxicity mediated by disruption of Ca2þ homeostasis in
neurons.50 This, along with oxidative stress leading to
increased MAP kinase activity, ultimately results in increased
phosphorylation of the protein Tau.51 Hyperphosphorylated
Tau then is incorporated into the neurofibrillary tangles seen in
Alzheimer’s disease. Amyloid processing incorporates these
events, which are important precipitants of neurodegeneration
in Alzheimer’s disease. That the protective THOP1 pathway
was present only in nondiabetic retinas while its counterpart,
amyloid processing, was unique to diabetic retinas lacking
markers for neurodegeneration may indicate a transitional role
for this pathway in the progression of DR.
Samples From Diabetic Donors With Glial
Activation
The ‘‘Dopamine Degradation’’ and ‘‘Parkinson’s Signaling’’
pathways were unique to retinas with abundant GA
(DþGFAP).
FIGURE 6. To evaluate the association of the identified proteins with neurological signaling, significant (B-H P value  0.001) signaling pathways
belonging to the category ‘‘Neurotransmitters and Other Nervous System Signaling’’ were selected for analysis. Comparison of the results obtained
for the three biological samples are shown here. Note: absence of a bar from any of the sample groups indicates that the pathway may have been
present but not significantly represented at the 0.001 B-H P value cutoff.
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Dopamine (DA) is released by a subclass of amacrine cells in
the retina25 and is involved in the diverse physiologic aspects
of retinal neuromodulation, mediation of light responsiveness,
and clock gene regulation.52,53 Disruption of the dopaminergic
system is classically associated with Parkinson’s disease, but it
also may occur in diabetes.
A reduction in the number of dopaminergic amacrine cells
was found in diabetic mouse retinas compared to nondiabetic
animals during early stages of diabetes.54–56 Furthermore,
treatment of diabetic mice with DA-restoring or DA-activating
drugs used in the treatment of Parkinson’s disease can restore
DA levels and significantly improve diabetes-associated visual
dysfunction in early stages of the disease.57
In addition to the identification of the ‘‘Dopamine
Degradation’’ and ‘‘Parkinson’s Signaling’’ pathways in the
DþGFAP group, we also found an associated decrease in b-
synuclein and increase in far upstream element-binding protein
1 (FBP-1). b-synuclein serves to inhibit a-synuclein aggregation
as well as a-synuclein nucleation, two crucial processes
involved in the pathogenesis of Parkinson’s disease. FBP-1 is
a Parkin protein substrate and accumulates in multiple
neurodegenerative diseases, including human autosomal reces-
sive juvenile Parkinson’s, Parkinson’s disease, and diffuse Lewy
body disease. However, the potential toxic effect of FBP-1 to
dopaminergic neurons has not been demonstrated.58 Finally, it
should be noted that, as occurs with Alzheimer’s disease, type
2 diabetic patients have an increased prevalence of Parkinson’s
disease and, therefore, the retina can serve as a window for the
pathophysiologic events that occur in the brain in these
neurodegenerative diseases.
Limitations of the Study
Our study has several limitations. First, the inferred pathways
require further confirmation in larger studies with more retinal
samples. Second, the presence of microvascular abnormalities
at death cannot be completely ruled out, but the absence of
apparent microangiopathy in the ophthalmologic examinations
performed 1 to 2 years before death makes this eventuality
very unlikely. Third, which cell types within the complex
cellular architecture of the retina contribute to the observed
changes must be elucidated. Finally, as occurs in all cross-
sectional studies, a direct causal role between the metabolic
pathways and development or progression of DR could not be
established. However, rather than any type of causality, our
objective was to identify a metabolic common signature
between retinal and brain neurodegeneration.
CONCLUSIONS
In conclusion, the proteomic analysis comparing retinas from
diabetic patients in preclinical stages of DR to those of healthy
controls has permitted us to identify several new pathways
involved in neuroregulation and neuroprotection. Further
studies addressed to examine the specific roles of these
proteins and pathways not only will increase our knowledge of
the pathogenesis of DR, but also could pave the way for new
therapeutic strategies against this devastating complication of
diabetes. In addition, several pathways shared with other
neurodegenerative disorders, such as Alzheimer’s and Parkin-
son’s disease, have been identified, thus, supporting that a
common soil exists in the neurodegenerative processes that
occur in the retina and brain. Finally, our findings support the
concept that the study of neurodegeneration in the diabetic
retina could be useful to further understand the neurodegen-
erative processes that occur in the brain of persons with
diabetes.
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